Loading
Led the proton dose-escalation trial in prostate cancer and the comparative-effectiveness debate over proton therapy.
Anthony Zietman led PROG 95-09, the randomised trial showing high-dose proton-boosted radiotherapy improves biochemical control in localised prostate cancer, and co-leads the PARTIQoL trial comparing protons with IMRT. He has championed evidence-based adoption of proton therapy, led bladder-preserving trimodality therapy at MGH, and edited the International Journal of Radiation Oncology, Biology, Physics.
| Title | Journal | Year |
|---|---|---|
| Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09 | JCO | 2010 |
| Particle therapy at the 'tipping point': an introduction to the Red Journal's special edition | International Journal of Radiation Oncology, Biology, Physics | 2016 |
Shares International Journal of Radiation Oncology, Biology, Physics, American Society for Radiation Oncology.
Shares IMRT / IGRT (modern external beam), Prostate cancer and the tags radiotherapy, prostate.
Shares IMRT / IGRT (modern external beam), Prostate cancer and the tags radiotherapy, prostate.
Shares Prostate cancer and the tags radiotherapy, prostate.
Shares Prostate cancer and the tags radiotherapy, prostate.
Shares Prostate cancer and the tags radiotherapy, prostate.
Shares Massachusetts General Hospital Cancer Center, Prostate cancer and the tag prostate.
Shares Proton therapy, IMRT / IGRT (modern external beam) and the tag radiotherapy.